QIAGEN Expands Liquid Biopsy Pipeline with AR-V7 Test in Prostate Cancer

HILDEN, Germany and GERMANTOWN, Maryland, March 31, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it is commercializing the Research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to investigate resistance to potential drugs for advanced prostate cancer. QIAGEN has acquired an exclusive worldwide license from Johns Hopkins University for detecting the AR-V7 biomarker in all sample and cell types through nucleic acid tests such as polymerase chain reaction (PCR) or next-generation sequencing (NGS). Johns Hopkins researchers have used AdnaTest technology in studies to evaluate the expression of AR-V7 messenger RNA in prostate cancer patients.

"Our AdnaTest workflow unlocks an important biomarker for clinical research to provide for the development of prostate cancer diagnostics in the future. Providing accurate insights from circulating tumor cells in a blood sample, our AR-V7 solution is a significant addition to our portfolio of non-invasive liquid biopsies for Personalized Healthcare," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area. "We are pleased to partner with the pioneering researchers at Johns Hopkins in developing this workflow. We plan to make the AdnaTest kit commercially available this year, as a Sample to Insight solution for clinical researchers."

Click here for the full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={55C014E9-91D1-4E5E-8FF0-822B2224081A}&lang=en

Contacts: 

QIAGEN 

Investor Relations            
John Gilardi    
+49-2103-29-11711        
e-mail: ir@QIAGEN.com             
           
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826  
e-mail: pr@QIAGEN.com

SOURCE QIAGEN N.V.